APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apellis Pharmaceuticals Inc (APLS) is not a strong buy for a beginner, long-term investor at this time. While there are some positive catalysts, the technical indicators are bearish, and the stock's recent performance has been weak. The lack of strong proprietary trading signals and mixed financial performance further support a hold recommendation.
The MACD histogram is negative and contracting, RSI is neutral at 36.634, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 17.096, with resistance at 19.025. Overall, the technical indicators suggest a bearish trend.
RTW Investments recently acquired a significant stake in Apellis, reflecting confidence in the company's growth potential. Hedge funds have increased their buying activity by 132.99% over the last quarter. Analysts see potential for long-term growth driven by Syfovre and Empaveli.
Technical indicators are bearish, and there is no recent congress trading data or strong proprietary trading signals.
In Q4 2025, revenue dropped by -5.94% YoY to $199.91 million. However, net income improved by 62.16% YoY to -$58.95 million, and EPS increased by 62.07% YoY to -0.47. Gross margin improved to 85.13%, up 5.38% YoY, indicating some operational efficiency gains.
Analysts have mixed views. Recent ratings include price targets ranging from $18 to $48, with some firms maintaining Buy ratings (e.g., H.C. Wainwright, Roth Capital) and others remaining Neutral (e.g., Mizuho, Wedbush). The average price target suggests potential upside, but near-term momentum is weak.
